Science for a Better Life A Global Leader in Health & Nutrition /////////// BMO Global Farm to Market Conference May 2022 / Bayer AG 1 /// Bayer AG /// BMO Global Farm to Market Conference /// May 2022 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual futur ...

/////////// Investor Conference Call Q1 2022 Results May 10th, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates gi ...

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, the Crop Science Division Stefan Oelrich - Head, the Pharmaceuticals Division Conference Call Participants Vincent Andrews - Morgan Stanley Pete Verdult - Citigroup Sachin Jain - Bank of America Michael Leuchten - UBS James Quigley - Morgan Stanley Keyur Parekh - Goldman Sachs Falko Friedrich - Deutsc ...

/////////// Investor Conference Call FY/Q4 2021 Results March 1, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates ...

Bayer AG (OTCPK:BAYZF) Q4 2021 Earnings Conference Call March 1, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - Chairman, CEO & Chief Sustainability Officer Rodrigo Santos - President, the Crop Science Division Wolfgang Nickl - CFO Stefan Oelrich - Head, the Pharmaceuticals Division Heiko Schipper - President, the Consumer Health Division Conference Call Participants Vincent Andrews - Morgan Stanley Peter Verdult - Citigroup Michael Leuchten - UBS Sachin Jain - Bank of America ...

1 /// JP Morgan Healthcare Conference /// January 10-13, 2022 40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 /////////// Stefan Oelrich Member of the Board of Management of Bayer AG President of the Pharmaceuticals Division Cautionary statements regarding forward-looking information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to mate ...

Financial Data and Key Metrics Changes - Group sales grew by 14% to €9.8 billion in Q3 2021, with strong contributions from all divisions [18] - EBITDA before special items increased by 16% to €2.1 billion, resulting in a margin of 21.4% [19] - Core earnings per share rose by 30% to €1.05 compared to the prior year quarter [19] - Free cash flow advanced to almost €2 billion in Q3, up from €1.2 billion in the previous year [21] - Year-to-date group sales increased by 9% to €33 billion, with EBITDA before special items at €8.8 billion, showing a 3% decline [22] Business Line Data and Key Metrics Changes - Crop Science reported impressive sales growth of 26% in Q3, driven by 14% from volume and 12% from price increases [24] - Pharma division sales increased by 7% to €4.5 billion, with Eylea contributing significantly with a 19% increase [26] - Consumer Health expanded sales to €1.3 billion, reflecting an 11% growth, with Nutritionals as the key growth driver [29] Market Data and Key Metrics Changes - Crop Science benefited from strong demand and tight supply, particularly for glyphosate-based herbicides in North America [24] - The company anticipates continued strong performance in Latin America for the upcoming season [36] Company Strategy and Development Direction - The company updated its guidance for 2021, expecting better topline growth for Crop Science and Consumer Health, while maintaining the outlook for Pharma [9] - The company is focused on innovation and sustainability, with significant investments in product launches and development of its late-stage pharma pipeline [11][16] - Bayer aims to provide 100 million women in low and middle-income countries with access to modern contraception by 2030 [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong underlying growth dynamics despite challenges from supply chain disruptions [48] - The company expects to see margin accretion going into 2022 due to pricing power and efficiency measures [74] - Management acknowledged the impact of inflation on costs but remains optimistic about passing on these costs to maintain margins [49] Other Important Information - Bayer's patent for Xarelto was maintained until mid-January 2026, which is expected to benefit the company in the coming years [10] - The company is preparing for the launch of ALZUO, a new steroid antihistamine nasal spray for allergies, expected in Q1 2022 [15] Q&A Session All Questions and Answers Question: Margin dynamics in Crop Science for Q4 - Management explained that Q3 benefited from lower returns and higher royalties, but Q4 may see a different dynamic due to a plant outage affecting glyphosate production [44][46] Question: Importance of finerenone data for KERENDIA - Management highlighted the significance of the FIGARO trial data in broadening the patient population for finerenone and mentioned ongoing clinical trials for heart failure [59] Question: Update on environmental science disposal - Management confirmed that the process for selling the environmental science asset is underway, with significant demand expected [114] Question: Sustainability of Consumer Health growth - Management indicated that while Q3 growth was exceptional, underlying dynamics suggest continued strength, particularly in Nutritionals [115]

/////////// Investor Conference Call Q3 2021 Results November 9, 2021 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates ...

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2021 Earnings Conference Call August 5, 2021 8:00 AM ET Company Participants Oliver Maier - Head-Investor Relations Werner Baumann - Chief Executive Officer Wolfgang Nickl - Chief Financial Officer Stefan Oelrich - President-Pharmaceuticals Division Liam Condon - President Crop Science Division Conference Call Participants Michael Leuchten – UBS Vincent Andrews – Morgan Stanley Joel Jackson – BMO Jo Walton – Credit Suisse James Quigley – Morgan Stanley Tony Jones – ...

| --- | --- | |------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Half-Year | | | Financial Report 2021 | Bayer: Strong growth, guidance upgrade | | | // Group sales at €10.9 billion (Fx & p adj. +12.9%) -- double-digit percentage growth | | | (Fx & p adj.) at all divisions // EBITDA before special items at €2.6 billion (--10.6%), burdened by currency effects ...